Disc Medicine posts smaller-than-expected Q1 net loss
Brief: Disc Medicine Announces Completion Of Enrollment Of Phase 3 Apollo Trial Of Bitopertin In Erythropoietic Protoporphyria
U.S. STOCKS ON THE MOVE-Hewlett Packard Enterprise, Dianthus, 3D Systems
U.S. STOCKS ON THE MOVE-Biotechs, Agilent, Dow
Biotechs gain as FDA vaccines chief's exit seen as easing regulatory pathway
Brief: Disc Medicine's Board Approves Restructuring Plan
Disc Medicine's 2025 net loss smaller than estimates
Disc to pursue traditional U.S. approval for bitopertin after FDA rejects new fast-track route (updated)
Disc Medicine to pursue traditional U.S. approval after FDA rejects new fast-track route
Brief: Disc Medicine Receives Complete Response Letter From FDA For Bitopertin For The Treatment Of EPP
Disc Medicine dives as FDA declines to approve rare disease drug
US FDA declines to approve Disc Medicine's rare disease drug (updated)
US FDA declines to approve Disc Medicine's rare disease drug
NASDAQ RESUMED AT 03:02 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:57 PM
NASDAQ RESUMED AT 02:52 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 02:31 PM
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns
US FDA delays two drug reviews in new voucher program after safety, efficacy concerns